When integrated with other pathological markers (e.g., p-tau181, p-tau217, and GFAP), APOA-I may enhance the sensitivity and specificity of diagnostic frameworks for both disease staging and cognitive monitoring in AD, which holds particular significance for AD MDT decisions. The gene discussed is APOA1; the disease is Alzheimer disease.